We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The need for more holistic immune profiling in nextgeneration SARS-CoV-2 vaccine trials.
- Authors
Murphy, Robert L.; Paramithiotis, Eustache; Sugden, Scott; Chermak, Todd; Lambert, Bruce; Montamat-Sicotte, Damien; Mattison, John; Steinhubl, Steve
- Abstract
First-generation anit-SARS-CoV-2 vaccines were highly successful. They rapidly met an unforeseen emergency need, saved millions of lives, and simultaneously eased the burden on healthcare systems worldwide. The first-generation vaccines, however, focused too narrowly on antibody-based immunity as the sole marker of vaccine trial success, resulting in large knowledge gaps about waning vaccine protection, lack of vaccine robustness to viral mutation, and lack of efficacy in immunocompromised populations. Detailed reviews of first-generation vaccines, including their mode of action and geographical distribution, have been published elsewhere. Second-generation clinical trials must address these gaps by evaluating a broader range of immune markers, including those representing cell-mediated immunity, to ensure the most protective and long-lasting vaccines are brought to market.
- Subjects
COVID-19 vaccines; VACCINE trials; VIRAL mutation; CELLULAR immunity; BIOMARKERS
- Publication
Frontiers in Immunology, 2022, Vol 13, p1
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2022.923106